Bionyra Pharma
Developing next-generation biologics for severe immunological and inflammatory diseases
$165MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Developing next-generation biologics for severe immunological and inflammatory diseases
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment